| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
CORRESPONDENCE |
Re: Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer
Affiliation of authors: Department of Epidemiology, Local Health Authority of Milan, Italy
Correspondence to: Antonio Russo, MD, Department of Epidemiology, Local Health Authority of Milan, Corso Italia 19, Milan 20122, Italy (e-mail: arusso@asl.milano.it).
| The first 10% of the full text of this article appears below. |
In a recent article, Hassett et al. (1) suggested that chemotherapy-related serious adverse effects among younger women with breast cancer may be more common than reported by large clinical trials. To confirm this finding, we estimated the frequency of chemotherapy-related serious adverse effects among all incident breast cancer cases (n = 3317) that occurred between January 1999 and
Related Article in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2006 98: 1108-1117.